Primer, probe and kit for detecting 2385 site polymorphism of LRRK2 gene

Abstract

The invention discloses a primer, a probe and a kit for detecting the 2385 site polymorphism of an LRRK2 gene. A pair of LRRK2 gene 2385 site specific primers is utilized to amplify human LRRK2 gene 2385 site gene segments, and a specific Taqman MGB probe is designed, that is, one SNP site is detected through two different channels in a reaction system. Under the condition that a reaction system contains different genotype templates, different fluorescence signals are released along with the PCR amplification process. And the signal intensity of a corresponding channel in the PCR process is monitored and output in real time by utilizing an instrument, so that qualitative analysis of a detection result is realized. On the basis of ensuring the detection specificity and sensitivity, convenient, rapid and efficient detection is realized, the detection operation steps are reduced, the detection reaction time is shortened, the production cost and the detection cost are reduced, and clinical detection analysis application is facilitated.

Description

technical field [0001] The invention relates to a primer, a probe and a kit for detecting LRRK2 gene 2385 polymorphism, belonging to the technical field of gene polymorphism detection. Background technique [0002] The human LRRK2 gene is located on chromosome 12p11.2–q13.1, is about 144kb (containing 7581 base pairs), contains 51 exons, and encodes a protein composed of 2527 amino acids (molecular weight is 275KDa), LRRK2 protein ( Also known as dardarin protein or leucine-rich repeat kinase 2), it belongs to the ROCO protein family. [0003] Parkinson's disease (PD) is currently the second most progressive neurodegenerative disease in the world. Certain mutations and risk variants of the leucine-rich repeat kinase 2 (LRRK2) gene are very common in PD patients, accounting for about 5-15% of familial and sporadic PD. So far, nearly 100 LRRK2 variants have been identified. Among them, G2019S, R1628P and G2385R have traditionally received a lot of attention. Each of these ...

AI Technical Summary

Problems solved by technology

[0008] Existing technology can only be detected by sequencing method. The machines and consumables required for sequencing are expensive, and the quality of operators is high. There is almost no sequencing service in ordinary hospitals, which is not conducive to the screening of genetic loci. Our genetic detection reagents The fluorescent quantitative PCR method is used, which is compatible with almost all fluorescent quantitative PCR instruments at present, and the fluorescent quantitative PCR technology has played an irreplaceable role in the new crown epidemic, becoming the mainstream of the detection industry, and the application prospect is very broad

[0009] At the level of clinical operations, there is currently no specific charging standard for related gene sequencing. Since high-throughput sequencing is suitable for simultaneous detection of multiple sites, the cost of detecting a single gene site is very high, so generally speaking, it is performed based on multiple sites. Fees, patients are under greater economic pressure

Images